指南与共识胸部肿瘤

肺癌诊断性免疫组化最佳实践推荐

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
指南 / 共识 · J Thorac Oncol · 2018-12-18

国际肺癌研究协会病理委员会针对肺癌诊断中免疫组化(IHC)的实际应用与判读问题,归纳出11个关键问题,涵盖非小细胞肺癌亚型鉴别的最佳标志物、甲状腺转录因子1克隆差异、少见亚型诊断及原发与转移鉴别等,提供专家解答与说明。

要点

  • IHC在肺癌诊断中作用突出,尤其用于低分化肿瘤的亚型鉴别以指导治疗选择。
  • 病理医师需认识IHC判读陷阱,并高效使用IHC以节省组织用于分子检测。
  • 本文以11个关键问题形式汇总日常实践中的诊断情形与挑战性问题的专家观点。

核心结论

  • 本文针对肺癌诊断中IHC应用与判读的关键问题提供解答与说明,代表胸部病理专家观点,应有助于业界在诊断病理中恰当使用IHC。

研究设计与样本

  • 国际肺癌研究协会(IASLC)病理委员会在多次委员会会议讨论后,将日常临床实践中的问题与注意事项归纳为11个关键问题。

主要发现

  • 自2015年WHO分类进入临床实践以来,IHC在肺癌诊断中作用突出。
  • IHC除用于小细胞癌与非小细胞癌的区分外,非小细胞癌的组织学亚型与患者治疗选择直接相关,尤其对低分化肿瘤。
  • IHC的使用提高了肺癌分类的诊断准确性,但某些情况下IHC结果的判读仍具挑战性。
  • 病理医师必须认识许多判读陷阱,且IHC的使用应高效以节省组织用于分子检测。
  • 11个关键问题涵盖非小细胞肺癌亚型鉴别的最佳IHC标志物、甲状腺转录因子1克隆差异、IHC诊断少见肺癌亚型及鉴别原发与转移肿瘤的效用等。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small cell versus non-small cell carcinoma, patients' treatment of choice is directly linked to histologic subtypes of non-small cell carcinoma, which pertains to IHC results, particularly for poorly differentiated tumors. The use of IHC has improved diagnostic accuracy in the classification of lung carcinoma, but the interpretation of IHC results remains challenging in some instances. Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The International Association for the Study of Lung Cancer Pathology Committee received questions on practical application and interpretation of IHC in lung cancer diagnosis. After discussions in several International Association for the Study of Lung Cancer Pathology Committee meetings, the issues and caveats were summarized in terms of 11 key questions covering common and important diagnostic situations in a daily clinical practice with some relevant challenging queries. The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors. This article provides answers and explanations for the key questions about the use of IHC in diagnosis of lung carcinoma, representing viewpoints of experts in thoracic pathology that should assist the community in the appropriate use of IHC in diagnostic pathology.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yatabe Y, Dacic S, Borczuk AC, et al. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol. 2018. PMID: 30572031. doi:10.1016/j.jtho.2018.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。